Clinical Trials Browser

Phase 1 × Unknown × Triple Negative Breast Neoplasms × Clear all

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05498597 2023-10-19

AMT-151 in Patients With Selected Advanced Solid Tumours

Phase 1 Unknown

30 enrolled

BreastGynecologicOther solid neoplasmThoracic

Adenocarcinoma of Lung, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Carcinoma, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05957939 2023-07-24

Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial

Phase 1 Unknown

2 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05692661 2023-01-20

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

Phase 1 Unknown

24 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03720431 2022-08-17

TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer

Phase 1 Unknown

11 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04460456 2022-06-30

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Phase 1 Unknown

58 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03251313 2022-04-20

PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

Phase 1 Unknown

31 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02637531 2022-04-04

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Phase 1 Unknown

219 enrolled

BreastDermatologicEndocrineOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Adrenocortical Carcinoma, Triple Negative Breast Neoplasms

NCT04142931 2021-03-24

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Phase 1 Unknown

30 enrolled

BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Triple Negative Breast Neoplasms

NCT04107142 2019-09-27

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Phase 1 Unknown

10 enrolled

BreastGastrointestinalGenitourinaryHead & NeckSarcoma

Nasopharyngeal Carcinoma, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02950064 2019-01-14

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

Phase 1 Unknown

95 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03076372 2018-02-27

A Study Evaluating MM-310 in Patients With Solid Tumors

Phase 1 Unknown

34 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02616848 2015-11-30

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Phase 1 Unknown

1 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02580747 2015-10-20

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

Phase 1 Unknown

20 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Ovarian Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

AMT-151 in Patients With Selected Advanced Solid Tumours

Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

A Study Evaluating MM-310 in Patients With Solid Tumors

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso